ECSP089023A - Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico - Google Patents

Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico

Info

Publication number
ECSP089023A
ECSP089023A EC2008009023A ECSP089023A ECSP089023A EC SP089023 A ECSP089023 A EC SP089023A EC 2008009023 A EC2008009023 A EC 2008009023A EC SP089023 A ECSP089023 A EC SP089023A EC SP089023 A ECSP089023 A EC SP089023A
Authority
EC
Ecuador
Prior art keywords
fenetil
amino
methyl
benzoic
carboxibutil
Prior art date
Application number
EC2008009023A
Other languages
English (en)
Inventor
Bernd Kuehn
Daniel Wagner
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ECSP089023A publication Critical patent/ECSP089023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una formulación farmacológica acuosa que contiene ácido 4-[((4-carboxibutil)-{2-[(4-fenetilbencil)oxi]fenetil}-amino) metil]benzoico o una de sus sales. En especial, la presente invención se refiere a una formulación farmacológica acuosa que contiene ácido 4-[((4-carboxibutil)-{2-[(4-fenetilbencil)oxi]fenetil}amino)metil]benzoico o una de sus sales y amino-2-(hidroximetil)-2-propanodiol-1,3 (trometamol).
EC2008009023A 2006-07-06 2008-12-30 Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico ECSP089023A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006031175A DE102006031175A1 (de) 2006-07-06 2006-07-06 Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur

Publications (1)

Publication Number Publication Date
ECSP089023A true ECSP089023A (es) 2009-01-30

Family

ID=38330492

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008009023A ECSP089023A (es) 2006-07-06 2008-12-30 Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico

Country Status (33)

Country Link
US (1) US20100069493A1 (es)
EP (1) EP2040691B1 (es)
JP (1) JP2009542589A (es)
KR (1) KR20090031546A (es)
CN (1) CN101484154A (es)
AR (1) AR061812A1 (es)
AT (1) ATE511837T1 (es)
AU (1) AU2007271431A1 (es)
BR (1) BRPI0714012A2 (es)
CA (1) CA2656630A1 (es)
CL (1) CL2007001960A1 (es)
CO (1) CO6160303A2 (es)
CR (1) CR10550A (es)
CY (1) CY1111881T1 (es)
DE (1) DE102006031175A1 (es)
DK (1) DK2040691T3 (es)
EC (1) ECSP089023A (es)
ES (1) ES2366389T3 (es)
GT (1) GT200800310A (es)
IL (1) IL195970A0 (es)
MA (1) MA30600B1 (es)
MX (1) MX2009000012A (es)
PE (1) PE20080554A1 (es)
PL (1) PL2040691T3 (es)
PT (1) PT2040691E (es)
RU (1) RU2009103818A (es)
SI (1) SI2040691T1 (es)
SV (1) SV2009003143A (es)
TN (1) TNSN08517A1 (es)
TW (1) TW200808690A (es)
UA (1) UA94955C2 (es)
UY (1) UY30471A1 (es)
WO (1) WO2008003414A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2115213A1 (en) * 2007-02-08 2009-11-11 Dow Global Technologies Inc. Flexible conductive polymeric sheet
DE102008062689A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Modifikation I der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
DE102008062688A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Monohydrat der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
PL2782914T3 (pl) 2011-11-25 2019-01-31 Adverio Pharma Gmbh Sposób wytwarzania podstawionych 5-fluoro-1H-pirazolopirydyn
BR112015001211B1 (pt) * 2012-07-20 2020-12-15 Bayer Pharma Aktiengesellschaft Ácidos 5-aminotetra-hidroquinolina-2-carboxílicos, processos para a sua preparação, seus usos no tratamento e/ou prevenção de doenças e seus medicamentos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination

Also Published As

Publication number Publication date
EP2040691B1 (de) 2011-06-08
PL2040691T3 (pl) 2012-01-31
DK2040691T3 (da) 2011-09-26
SV2009003143A (es) 2009-07-28
TNSN08517A1 (en) 2010-04-14
EP2040691A1 (de) 2009-04-01
CL2007001960A1 (es) 2008-02-01
MX2009000012A (es) 2009-01-23
RU2009103818A (ru) 2010-08-20
DE102006031175A1 (de) 2008-01-10
CA2656630A1 (en) 2008-01-10
CR10550A (es) 2009-06-04
AU2007271431A1 (en) 2008-01-10
CO6160303A2 (es) 2010-05-20
AR061812A1 (es) 2008-09-24
ES2366389T3 (es) 2011-10-19
MA30600B1 (fr) 2009-07-01
CN101484154A (zh) 2009-07-15
BRPI0714012A2 (pt) 2013-04-02
CY1111881T1 (el) 2015-11-04
UA94955C2 (en) 2011-06-25
SI2040691T1 (sl) 2011-10-28
WO2008003414A1 (de) 2008-01-10
UY30471A1 (es) 2008-02-29
KR20090031546A (ko) 2009-03-26
PE20080554A1 (es) 2008-07-13
GT200800310A (es) 2009-07-31
TW200808690A (en) 2008-02-16
IL195970A0 (en) 2009-09-01
US20100069493A1 (en) 2010-03-18
PT2040691E (pt) 2011-08-23
JP2009542589A (ja) 2009-12-03
ATE511837T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
FR25C1030I2 (fr) Sels de lysine de derives d'acide 4-((phenoxyalkyl) thio)-phenoxyacetique
ECSP089023A (es) Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico
CR8218A (es) Antidoto sobre la base de derivados de acidos carboxilicos aromaticos alifaticos
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
BRPI0609636A2 (pt) formulações farmacêuticas
MA29416B1 (fr) Inhibiteurs d'age
BRPI0418133A2 (pt) pró-fármaco de florfenicol tendo solubilidade em água melhorada
UY30301A1 (es) Ácidos bifenilcarboxílicos substituidos y sus derivados
SV2010003770A (es) Composicion y proceso- 356
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
ATE519737T1 (de) Organische verbindungen
CU20080249A7 (es) Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"
BR0307009A (pt) Sais estáveis de ácido o-acetilsalicìlico com aminoácidos básicos ii
DOP2008000090A (es) Formulacion farmacologica acuosa de acido 4-[((4-carboxibutil)-(2-[(4-fenetil-bencil(oxi]-fenetil)amino]benzoico
BR0317834A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìlico como inibidores mmp 13 seletivos
CY1112023T1 (el) Φαρμακοτεχνικη μορφη νιτροοξυπαραγωγων των nsaids
AR063597A1 (es) Nueva sal
AR066696A1 (es) Sales de picotamida. composiciones farmaceuticas.
TH95774A (th) สูตรผสมทางเภสัชกรรมชนิดน้ำของ 4-[((4-คาร์บอกซีบิวทิล)-{2-[(4-เฟนเนทธิลเบนซิล)ออกซี]เฟนเนทธิล}อะมิโน)เมทธิล]เบนโซอิคแอซิด
UY31226A1 (es) Nuevos polimorfos de los compuestos 2-{2-cloro-5-{[2s-3-(5-cloro-1??h, 3h-espiro[1,benzofurano-2,4??piperidina]-1??yi)-2-hidroxipropilo]oxi}-4-[(aminometilico)fenoxicarbonilo}-2-acido metilpropanoico, y sus sales clorhidrato e hidroxido de sodio, y c